ARTICLE | Clinical News

Scancell preclinical data

September 20, 2010 7:00 AM UTC

In a mouse model of melanoma, Scancell's SCIB1 ImmunoBody vaccine in combination with Homspera from ImmuneRegen BioSciences Inc. (OTCBB:IRBS, Scottsdale, Ariz.) significantly improved the immune response to the vaccine compared to vaccine alone. Homspera is an analog of the naturally occurring immunomodulator substance P in preclinical testing. Scancell started Phase I testing of SCIB1 to treat melanoma in June. ...